Veradigm examines pre-diagnostic gaps in testicular cancer assessment for young men

Veradigm examines pre-diagnostic gaps in testicular cancer assessment for young men
Veradigm studies cancer test gaps

Veradigm has released new research focusing on the period before a testicular cancer diagnosis, specifically looking at gaps in testing and evaluation for young men.

The company’s findings are being presented at the ISPOREU2026 conference and aim to shed light on potential shortcomings in diagnostic practices for this demographic.

Veradigm has previously investigated early-stage testing gaps in young men with testicular cancer, sharing related findings at ISPOR EU 2026. The company has also earned HITRUST i1 certification for 16 healthcare solutions, demonstrating its ongoing focus on data security and compliance across its platform. These initiatives reflect Veradigm's continued engagement with both clinical research and regulatory standards.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.